Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization
about
DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in transAccess of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseasesThe molecular basis of HIV entryAntibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexesAntibody binding in proximity to the receptor/glycoprotein complex leads to a basal level of virus neutralization.Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans.Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelopeInduction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages.Functional and antigenic characterization of human, rhesus macaque, pigtailed macaque, and murine DC-SIGN.Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition.Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociaInduction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection.Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization.Neutralisation of HIV-1 cell-cell spread by human and llama antibodies.The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.A post-entry role for CD63 in early HIV-1 replicationCharacterization of HIV-1 envelope gp41 genetic diversity and functional domains following perinatal transmission.Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120.Design, synthesis and application of benzyl-sulfonate biomimetic affinity adsorbents for monoclonal antibody purification from transgenic corn.Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals.Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-DependentChlamydia trachomatis Infection of Endocervical Epithelial Cells Enhances Early HIV Transmission Events.Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry.HIV-1 membrane fusion: targets of opportunityCost-effective production of a vaginal protein microbicide to prevent HIV transmission.Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.
P2860
Q24601035-FCDD0DDA-5F56-4C9F-8B72-72AAC778EE43Q24645530-DF237FEE-8889-432E-AFE1-F0EE360036D6Q26783175-7A565A8B-BF85-4CCF-A194-9A2840BFDF2CQ26863686-A25988DB-9E1B-48D3-99B4-62BFA49C5B59Q27756974-9C8E9534-1475-4B3F-AC4B-5CB57D1D03E6Q30444158-3718A49C-5605-4BF4-8482-9E839B9343BEQ30490942-06B502A3-F31F-4894-B7EB-1B47ED4BE8D8Q33648180-ED788545-C508-43B9-B7B1-BD23DCF4028DQ33781055-4C380DBA-3EC5-4AF4-A109-FD4663178044Q33782556-E9C0B14D-430E-4442-AA1E-0F55775D7558Q33782608-BD58FD77-3CF7-431D-86A1-2A6C0292C954Q33783714-953A083A-1F0C-4C8D-956C-0DAD70F37E92Q33784777-BA544AE5-BCC2-42D5-9513-D0ED6AF573EBQ33788792-262D749F-A92E-4B67-B00F-554263F788BBQ33813212-2BDED4D0-6813-4BF8-BCB1-C9097D0F7536Q33839402-9754568E-DE22-42C1-A548-E4790048EFF5Q33842286-8328660F-553D-4665-89CC-65D3593BCCCEQ33845503-517CF26D-D2E7-4141-995F-F7A8A8241CC7Q33847871-91529618-4DB3-4523-9A92-5591C37B580BQ33850612-CCAE4F18-D2E7-4435-9040-065C46F74A88Q33981547-6DB2DF0F-E5F9-48B1-928E-1E19F5B0A58DQ34142795-A05402A9-06F0-480C-B429-C4F97030EF77Q34203163-2BFC3312-50AD-4FB9-B132-2EC4D625DFA7Q34284855-87FD5F1E-AD61-4E2C-BD21-DB05018A6201Q34304203-C34573CE-9098-4559-A108-0E6F75759732Q34341843-913C9148-89F7-46A6-BC13-5389EF9BCEF0Q34462299-08486F87-B570-4784-9DFD-8793B02C5A86Q34552313-A0E30A10-98E6-4D74-B97A-579D5B959BCAQ34699365-FE276C2D-3C9E-4903-AAFE-DD857D5D2632Q34899225-061B27CC-F342-4392-8F83-6E771292C8D5Q34983331-F5BDE899-549A-4383-820D-A3390EC5AC86Q35077349-5E880BDA-D3D4-42B0-9219-4FC2FFA689ACQ35140032-F4DD799C-58AB-4E43-B8EF-9DE8A80A921CQ35585401-01FDD0C2-F36B-4146-8A99-410A673E01F4Q35686912-C204E461-C964-4C5B-8EAA-1AD7F235AD6FQ35885053-154D4654-0CB0-4DCB-B71B-28FDCCD7D6E2Q35974165-4CFCBCF1-4016-4FE5-B2E0-A6A411286109Q36366904-7A85AB94-6A9F-43BD-B813-D400A91EEF36Q36499053-95B8EC87-CAE5-406C-AF31-EB809B6A2EC4Q36541239-73BA97B9-F525-4D1B-8009-8CB272BF58DA
P2860
Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Inhibition of virus attachment ...... e-adapted HIV-1 neutralization
@ast
Inhibition of virus attachment ...... e-adapted HIV-1 neutralization
@en
type
label
Inhibition of virus attachment ...... e-adapted HIV-1 neutralization
@ast
Inhibition of virus attachment ...... e-adapted HIV-1 neutralization
@en
prefLabel
Inhibition of virus attachment ...... e-adapted HIV-1 neutralization
@ast
Inhibition of virus attachment ...... e-adapted HIV-1 neutralization
@en
P2093
P2860
P356
P1476
Inhibition of virus attachment ...... e-adapted HIV-1 neutralization
@en
P2093
D R Burton
P J Klasse
Q J Sattentau
S A Tilley
P2860
P304
P356
10.1084/JEM.186.8.1287
P407
P577
1997-10-01T00:00:00Z